Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Adult-Onset Still’s Disease with Complications

Cristina Romaniello, DO, & Caitlin Kesari, MD  |  Issue: February 2023  |  February 14, 2023

The classic description of symptoms includes arthritis, fever, evanescent rash and elevated ferritin levels. However, patients may also present with other clinical features, including sore throat, hepatomegaly, splenomegaly, lymphadenopathy and serositis.6

The disease course generally follows one of three patterns: 1) a singular, self-limited episode (i.e., monocyclic); 2) a pattern of continued flares with periods of remission (i.e., polycyclic); and 3) continued signs and symptoms with no periods of remission (i.e., chronic).3 At almost two years from initial diagnosis, our patient’s disease remains in remission; thus, he follows the monocyclic pattern.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are no specific tests that confirm a diagnosis of AOSD; however, laboratory tests commonly show non-specific signs of generalized inflammation, including anemia, thrombocytosis, elevated inflammatory markers and significantly elevated ferritin. Of note, ferritin is usually markedly elevated and found to be much higher than in other autoimmune, infectious, inflammatory or neoplastic diseases. Higher levels of ferritin may also be an indicator of MAS.5

Click to enlarge.

Although AOSD is largely a clinical diagnosis, clinicians can use the Yamaguchi criteria and Fautrel criteria to help classify it. As seen in Table 1, the Yamaguchi criteria require that five or more criteria be met, with at least two major criteria, and infection, malignancies and other rheumatic diseases ruled out.13 The Yamaguchi criteria has a sensitivity of 96.2% and a specificity of 92.1% in diagnosing AOSD.13

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As seen in Table 2, the Fautrel criteria require at least four or more major criteria or three major criteria with two minor criteria be met. They have a sensitivity of 80.6% and specificity of 98.5%.4

Our patient’s disease characteristics fit both the Fautrel criteria and the Yamaguchi criteria because he had fever (>39ºC), leukocytosis with 96%, polymorphonuclear neutrophils, polyarthralgia/arthritis, abnormal liver function tests, pharyngitis and rash. In addition, his infectious and hematologic evaluations were negative, ruling out other causes of his presentation.

Click to enlarge.

The treatment aim for AOSD is to control inflammation and prevent end-organ damage, which can be assessed clinically and through serial measurement of inflammatory markers. The treatment initiated depends on disease severity. Patients are classified as having mild to moderate disease when symptoms are low grade, including mild fever, rash and arthralgias or arthritis. These patients may be treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, NSAIDs alone fail to control symptoms in 80% of AOSD patients.9 If symptoms fail to improve after a two week trial of NSAIDs, glucocorticoids are recommended for management in mild cases.9

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:adult Still's Diseasecase reportmacrophage activation syndrome

Related Articles

    Macrophage Activation Syndrome

    December 1, 2010

    A review of diagnosis, treatment, and prognosis

    New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis

    August 10, 2016

    Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…

    2014 ACR/ARHP Annual Meeting: Macrophage Activation Syndrome

    April 1, 2015

    The pathogenesis of and new classification criteria for MAS

    Case Report: Intermittent Fevers in a Patient with pJIA

    April 15, 2022

    A 26-year-old woman presented to our emergency department (ED) with intermittent fevers, nausea and vomiting. She had a past medical history of well-controlled, anti-nuclear antibody positive and rheumatoid factor negative polyarticular juvenile idiopathic arthritis (pJIA) and Crohn’s disease. Her maintenance treatment consisted of monthly intravenous infliximab, 10 mg of oral methotrexate weekly and 20 mg…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences